KOSDAQBiotech & Pharma321550

TiumBio

₩3,360▲ 0.45%2026-11-18 close
Market Cap
₩100.9B
Turnover
₩100M
Volume
40K
Shares out.
30M
PER
—
PBR
3.2×
EPS
-₩567
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

TiumBio: Pipeline Validation Ahead of a Profit Turn

TiumBio's revenue reached KRW 12.3 billion in 2025 and has grown for two straight years, but operating losses have continued for four years, so clinical progress on Tosposertib and the outcome of Merigolix licensing talks are the next checkpoints.

  1. 1

    2025 revenue was KRW 12.3 billion, up 80.9% year on year, and the company attributes much of the increase to roughly KRW 4.9 billion from the Petraon Care Lab business merged at the end of 2024.

  2. 2

    Operating loss narrowed to KRW 16.1 billion in 2025, but the company has posted losses for four consecutive years, and the four most recent quarters total KRW 18 billion in net loss attributable to controlling shareholders.

  3. 3

    Tosposertib (TU2218) received FDA Fast Track designation on November 4, 2026, and its Phase 2a data in first-line recurrent or metastatic head and neck cancer with Keytruda showed a 75% objective response rate.

  4. 4

    Global licensing of Merigolix (TU2670) is reported to be in discussion, and a KRW 30 billion convertible bond issuance was also reported as a funding plan.

02

Business structure

TiumBio runs two revenue businesses alongside its drug pipeline. The first is bio-process development and contract development and analysis (CDAO) services run by its subsidiary Protium Science, in which it holds a 68.36% stake.

The second is the Petraon Care Lab natural cosmetics unit, created after the merger of Petraon at the end of 2024, whose key customers include Ananti and the eco-beauty brand Tone28.

In the first half of 2026, bio-pharmaceutical development and manufacturing revenue was KRW 5.3 billion and natural cosmetics revenue was KRW 2.1 billion according to the semiannual report.

Its lead pipeline assets are Tosposertib (TU2218), an oral immuno-oncology candidate that inhibits TGF-β and VEGF, Merigolix (TU2670) for endometriosis and uterine fibroids, and TU7710 for hemophilia.

Tosposertib is being tested with MSD's Keytruda, and R&D spending in the first half of 2026 was KRW 5.5 billion, about 73% of revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.1B-₩4.5B−144.8%
2025Q4₩4.4B-₩2.8B−62.6%
2026Q1₩3B-₩4.5B−153.8%
2026Q2₩4.5B-₩4.2B−94.8%
2026Q3₩3.8B-₩3.2B−83.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.1B-₩25.6B-₩31.4B−281.2%−51.4%54.5%
2023₩4.9B-₩27.8B-₩19B−568.1%−27.2%69.9%
2024₩6.8B-₩18.7B-₩23.5B−275.3%−44.9%111.4%
2025₩12.3B-₩16.1B-₩18.8B−131.4%−46.0%161.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue fell from KRW 9.12 billion in 2022 to KRW 4.9 billion in 2023, a 46.3% decline, then rose to KRW 6.79 billion in 2024 (up 38.7%) and KRW 12.3 billion in 2025 (up 80.9%).

Revenue has grown for two consecutive years from 2024 through 2025, with 2025 the largest year and 2023 the smallest in the 2022–2025 period. The company attributes the 2025 increase to about KRW 4.9 billion from the Petraon Care Lab business and a roughly KRW 350 million rise at subsidiary Protium Science.

Operating loss was KRW 25.6 billion in 2022, KRW 27.8 billion in 2023 (wider), KRW 18.7 billion in 2024 (narrower) and KRW 16.1 billion in 2025 (narrower), a four-year run of losses. Operating margin moved from -281.2% in 2022 to -568.1% in 2023, then improved to -275.3% in 2024 and -131.4% in 2025.

Net loss attributable to controlling shareholders was KRW 31.4 billion in 2022, KRW 19 billion in 2023, KRW 23.5 billion in 2024 and KRW 18.8 billion in 2025.

Quarterly operating losses were KRW 4.52 billion in Q3 2025, KRW 2.79 billion in Q4 2025, KRW 4.54 billion in Q1 2026, KRW 4.24 billion in Q2 2026 and KRW 3.17 billion in Q3 2026, five consecutive loss quarters.

Quarterly revenue dipped to KRW 2.95 billion in Q1 2026, rebounded to KRW 4.48 billion in Q2 and was KRW 3.81 billion in Q3, up 22.0% from a year earlier.

The debt ratio rose from 54.5% in 2022 to 161.1% in 2025, with total liabilities of KRW 60.8 billion and total equity of KRW 37.7 billion at year-end 2025, of which controlling shareholders hold KRW 40.8 billion. Operating cash flow was negative every year from 2022 to 2025.

05

Industry analysis

TiumBio's demand side is pharma licensing of clinical-stage assets. The company has set 2026 as the year to commercialize three clinical-stage pipeline assets and is pursuing global licensing.

DB Securities said in a March 2026 report that the company has proven technology in the clinic and must now prove business value through licensing deals.

In a February 2026 report, the Korea IR Association said valuation should center on clinical progress and global licensing potential rather than near-term earnings, and it did not present an investment rating or target price.

Tosposertib is being developed in combination with Keytruda, and the company compares its progression-free survival data with Keytruda alone and with chemotherapy combinations, though these are early Phase 2a results from a small patient group.

Merigolix reached statistically significant primary endpoints in a European Phase 2a endometriosis study, and its domestic uterine fibroid Phase 2 has been completed.

06

Outlook

The company's stated 2026 focus is securing commercial milestones through global licensing of its main pipeline assets.

After the FDA Fast Track designation for Tosposertib, the company said it will refine its follow-on trial design and approval strategy with the FDA, while pursuing a global Phase 2b study and partnering with overseas pharma companies.

It had earlier set entry into a Phase 2b study in 2026 as a target and said it was in active talks with global big pharma on joint R&D or licensing before that step. For Merigolix, the company said it is working to finalize talks with potential partners for the major markets of endometriosis and uterine fibroids.

A convertible bond of KRW 30 billion was reported as a funding plan, with proceeds directed to Merigolix, Tosposertib and TU7710 R&D. The next confirmations are whether Tosposertib enters Phase 2b, whether a Merigolix licensing deal is signed, and whether the operating loss keeps narrowing in the 2026 annual results.

07

Valuation

PER
—
PBR
3.2×
ROE
-51.4%
EPS
-₩567
BPS
₩1,069
Dividend per share
₩0

Price-to-earnings cannot be calculated because net losses over the most recent four quarters leave no earnings base, so valuation rests on book value and pipeline progress together.

Price-to-book sits at a premium to book value attributable to controlling shareholders, which can be read as reflecting pipeline expectations not captured in the balance sheet. At year-end 2025, total equity was smaller than the equity attributable to controlling shareholders, so non-controlling interests are negative.

The dividend yield is in the 0% range, so it does not function as a shareholder-return measure. Over several years, operating losses narrowed from KRW 25.6 billion in 2022 to KRW 16.1 billion in 2025, while the debt ratio rose from 54.5% to 161.1%.

The Korea IR Association, in a February 2026 report, said valuation should focus on clinical progress and licensing potential, and DB Securities said in March 2026 that licensing deals are needed to prove business value.

Both views rely on pipeline progress rather than earnings multiples, so the current multiple will be read differently depending on licensing outcomes.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Expanding revenue base

Revenue reached KRW 12.3 billion in 2025, up 80.9%, and has grown for two straight years from 2024 through 2025. The CDAO business and the newly consolidated natural cosmetics unit together help offset part of the R&D spending.

Clinical data and regulatory milestone

Tosposertib received FDA Fast Track designation on November 4, 2026. Its Phase 2a data showed a 75% objective response rate, with one complete response and eight partial responses among 12 patients, and a median progression-free survival of 10.9 months.

Licensing track record and pipeline breadth

Merigolix has licensing precedents with Daewon Pharm in 2019 and Hansoh in 2022, reached statistical significance in a European Phase 2a endometriosis study, and completed its domestic uterine fibroid Phase 2. Together with Tosposertib and TU7710, the company has several clinical-stage assets.

09

Bear factors

Persistent operating losses

Operating losses have run for four consecutive years, with KRW 16.1 billion in 2025. Net losses attributable to controlling shareholders over the last four quarters total KRW 18 billion, and R&D spending in the first half of 2026 was about 73% of revenue, so costs remain well ahead of sales growth.

Rising leverage and funding needs

The debt ratio rose from 54.5% in 2022 to 161.1% in 2025, with total liabilities of KRW 60.8 billion at year-end 2025. A KRW 30 billion convertible bond was reported, with a refixing clause, so further funding could dilute existing shareholders.

Clinical evidence still early

Tosposertib's response rate comes from interim Phase 2a data with 12 evaluable patients, and the Phase 2b design and approval strategy are still being developed. Merigolix licensing is reported as under discussion rather than signed, and quarterly revenue swung between KRW 2.95 billion and KRW 4.48 billion in 2026.

10

Risk factors

Clinical and regulatory risk

Tosposertib's results come from small interim data sets. Fast Track designation does not guarantee approval, and late-stage trial design depends on consultations with regulators. Whether the company enters Phase 2b as targeted for 2026 is a key confirmation point.

Funding and dilution risk

With operating losses continuing, a KRW 30 billion convertible bond was reported. Conversions would dilute existing shareholders. The company says most of its debt consists of preferred shares and exchangeable bonds at subsidiary Protium Science and views repayment risk as minor.

Revenue concentration risk

Revenue in 2025 came mainly from the CDAO and natural cosmetics businesses, and the cosmetics unit depends on a limited group of customers. Until licensing income from the drug pipeline becomes material, sales depend on order flow in these two businesses.

11

What to watch next

  1. By December 31, 2026 (company target)

    Whether Tosposertib enters Phase 2b, a step the company set as a 2026 target; entry would mark the start of late-stage development.

  2. Timing undetermined (after November 2026)

    Whether a global licensing agreement for Merigolix is signed; disclosed terms and upfront payments would become the basis for assessing pipeline value.

  3. Around mid-February 2027 (last year's preliminary results were disclosed on February 11, 2026)

    Whether 2026 annual revenue keeps rising and how far operating losses narrow, based on preliminary results released before the full annual report.

  4. By March 31, 2027 (annual report filing deadline)

    The 2026 annual report will show audited operating loss, debt ratio and operating cash flow, which will be compared with 2025 levels.

12

Overall view

TiumBio grew revenue to KRW 12.3 billion in 2025, up 80.9%, with growth in two consecutive years, but operating losses of KRW 16.1 billion mean four straight years of losses continue.

Revenue comes mainly from the CDAO and Petraon Care Lab cosmetics businesses, while drug pipeline monetization is still at the licensing stage. Tosposertib has advanced with FDA Fast Track designation and interim combination data with Keytruda, but its data size and follow-on trial design need further confirmation.

Financially, the debt ratio rose to 161.1%, and a convertible bond was reported, so the funding path has become important. Positive and negative factors coexist, so no single conclusion is clear.

The next checkpoints are Tosposertib's Phase 2b entry, the signing of a Merigolix licensing deal and the trend in 2026 annual operating loss.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. medicopharma.co.kr
  2. comp.fnguide.com
  3. view.asiae.co.kr
  4. mt.co.kr
  5. news.nate.com
  6. comp.wisereport.co.kr
  7. v.daum.net
  8. dailyinvest.kr
  9. biobookmedia.com
  10. view.asiae.co.kr
  11. newspim.com
  12. edaily.co.kr
  13. m.news.nate.com
  14. wowtv.co.kr
  15. news.nate.com
  16. v.daum.net
  17. tiumbio.com
  18. news1.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis